NCT00934427 is a Phase 3 clinical trial of 0.9% nitroglycerin in TAM cream in Raynaud Disease, sponsored by MediQuest Therapeutics.

Who is sponsoring NCT00934427?

NCT00934427 is sponsored by MediQuest Therapeutics.

What drugs are being tested in NCT00934427?

Interventions in NCT00934427: 0.9% nitroglycerin in TAM cream, vehicle cream.

What condition does NCT00934427 study?

NCT00934427 studies Raynaud Disease.

Is NCT00934427 still recruiting?

NCT00934427 is currently status unknown. Last updated 19 July 2010.

Last reviewed 2010-07-19 · How we verify

NCT00934427

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon

Status unknown Phase 3 Last updated 19 July 2010

What this trial tests

Phase 3 trial testing 0.9% nitroglycerin in TAM cream in Raynaud Disease in 100 participants. Status unknown.

Timeline

1 June 2009

Primary endpoint
1 June 2010

1 July 2010

Quick facts

Lead sponsor	MediQuest Therapeutics
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 June 2009
Primary completion	1 June 2010
Estimated completion	1 July 2010
Sites	11 locations across United States

Drugs / interventions tested

0.9% nitroglycerin in TAM cream — full drug profile →
vehicle cream — full drug profile →

Conditions studied

Raynaud Disease — all drugs for Raynaud Disease →

Sponsor

MediQuest Therapeutics — full company profile →

Who can join

Adults 18 to 70, any sex, with Raynaud Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response rate as measured by changes in severity of the Raynaud's symptom most bothersome to the individual patient (Pain, Numbness, or Tingling)
Time frame: 2 weeks

Sponsor's own description

The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Raynaud Disease

Currently open trials in the same condition.

NCT06989216 — Multi-modal Quantitative Imaging of the Skin · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00934427 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MediQuest Therapeutics
Last refreshed: 19 July 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00934427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing